Use of immunohistochemistry in diagnosis of breast epithelial lesions

Advances in Anatomic Pathology

Volumn 14, Issue 2, 2007, Pages 93-107

  Bhargava, Rohit ^a   Dabbs, David J ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Breast epithelial lesions; Diagnostic immunohistochemistry

Indexed keywords

CYTOKERATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; VIMENTIN;

ADJUVANT CHEMOTHERAPY; BREAST CARCINOMA; BREAST EPITHELIUM; BREAST LESION; CANCER DIAGNOSIS; CANCER INVASION; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; GENE EXPRESSION; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH VESSEL; LYMPHATIC SYSTEM; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PAGET BONE DISEASE; PARTIAL MASTECTOMY; PATHOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SENTINEL LYMPH NODE;

ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CARCINOMA; CELL PROLIFERATION; DIAGNOSIS, DIFFERENTIAL; EPITHELIUM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; MELANOMA; PAGET'S DISEASE, MAMMARY; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 34247639140     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0b013e31803244d5     Document Type: Review

References (162)

1. Nakane PK, Pierce GB Jr. Enzyme-labeled antibodies for the light and electron microscopic localization of tissue antigens. J Cell Biol. 1967;33:307-318.
2. Cheng L, Binder SW, Fu YS, et al. Demonstration of estrogen receptors by monoclonal antibody in formalin-fixed breast tumors. Lab Invest. 1988;58:346-353.
3. Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17:1474-1481.
4. McCarty KS Jr, Miller LS, Cox EB, et al. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985;109:716-721.
5. Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11:155-168.
6. Diaz LK, Sneige N. Estrogen receptor analysis for breast cancer: current issues and keys to increasing testing accuracy. Adv Anat Pathol. 2005;12:10-19.
7. Press MF, Sauter G, Bernstein L, et al. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res. 2005;11:6598-6607.
8. Shi SR, Liu C, Taylor CR. Standardization of immunohistochemistry for formalin-fixed, paraffin-embedded tissue sections based on the antigen retrieval technique: from experiments to hypothesis. J Histochem Cytochem. DOI: 10.1369/jhc.6P7080.2006. [Epub ahead of print].
9. Taylor CR. Standardization in immunohistochemistry: the role of antigen retrieval in molecular morphology. Biotech Histochem. 2006;81:3-12.
10. Acs G, Wang L, Raghunath PN, et al. Role of different immunostaining patterns in HercepTest interpretation and criteria for gene amplification as determined by fluorescence in situ hybridization. Appl Immunohistochem Mol Morphol. 2003;11:222-229.
11. Bhargava R, Naeem R, Marconi S, et al. Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression. Hum Pathol. 2001;32:1344-1350.
12. Perez EA, Roche PC, Jenkins RB, et al. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc. 2002;77:148-154.
13. Garcia-Caballero T, Menendez MD, Vazquez-Boquete A, et al. HER-2 status determination in breast carcinomas. A practical approach. Histol Histopathol. 2006;21:227-236.
14. Tsuda H, Akiyama F, Terasaki H, et al. Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinoma. Interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression. Cancer. 2001;92:2965-2974.
15. Tubbs RR, Pettay JD, Roche PC, et al. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol. 2001;19:2714-2721.
16. Chorn N. Accurate identification of HER2-positive patients is essential for superior outcomes with trastuzumab therapy. Oncol Nurs Forum. 2006;33:265-272.
17. Mass RD, Press MF, Anderson S, et al. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer. 2005;6:240-246.
18. Fechner RE. Lobular carcinoma in situ in sclerosing adenosis. A potential source of confusion with invasive carcinoma. Am J Surg Pathol. 1981;5:233-239.
19. Rasbridge SA, Millis RR. Carcinoma in situ involving sclerosing adenosis: a mimic of invasive breast carcinoma. Histopathology. 1995;27:269-273.
20. Barbareschi M, Pecciarini L, Cangi MG, et al. p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Am J Surg Pathol. 2001;25:1054-1060.
21. Kalof AN, Tam D, Beatty B, et al. Immunostaining patterns of myoepithelial cells in breast lesions: a comparison of CD10 and smooth muscle myosin heavy chain. J Clin Pathol. 2004;57:625-629.
22. Kovacs A, Walker RA. P-cadherin as a marker in the differential diagnosis of breast lesions. J Clin Pathol. 2003;56:139-141.
23. Moritani S, Kushima R, Sugihara H, et al. Availability of CD10 immunohistochemistry as a marker of breast myoepithelial cells on paraffin sections. Mod Pathol. 2002;15:397-405.
24. Werling RW, Hwang H, Yaziji H, et al. Immunohistochemical distinction of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain. Am J Surg Pathol. 2003;27:82-90.
25. Koker MM, Kleer CG. p63 expression in breast cancer: a highly sensitive and specific marker of metaplastic carcinoma. Am J Surg Pathol. 2004;28:1506-1512.
26. Hill CB, Yeh IT. Myoepithelial cell staining patterns of papillary breast lesions: from intraductal papillomas to invasive papillary carcinomas. Am J Clin Pathol. 2005;123:36-44.
27. Papotti M, Eusebi V, Gugliotta P, et al. Immunohistochemical analysis of benign and malignant papillary lesions of the breast. Am J Surg Pathol. 1983;7:451-461.
28. Raju UB, Lee MW, Zarbo RJ, et al. Papillary neoplasia of the breast: immunohistochemically defined myoepithelial cells in the diagnosis of benign and malignant papillary breast neoplasms. Mod Pathol. 1989;2:569-576.
29. Saddik M, Lai R. CD44s as a surrogate marker for distinguishing intraductal papilloma from papillary carcinoma of the breast. J Clin Pathol. 1999;52:862-864.
30. Carter D, Orr SL, Merino MJ. Intracystic papillary carcinoma of the breast. After mastectomy, radiotherapy or excisional biopsy alone. Cancer. 1983;52:14-19.
31. Carter D. Intraductal papillary tumors of the breast: a study of 78 cases. Cancer. 1977;39:1689-1692.
32. Collins LC, Carlo VP, Hwang H et al. Intracystic papillary carcinomas of the breast: a reevaluation using a panel of myoepithelial cell markers. Am J Surg Pathol. 2006;30:1002-1007.
33. Leal C, Costa I, Fonseca D, et al. Intracystic (encysted) papillary carcinoma of the breast: a clinical, pathological, and immunohistochemical study. Hum Pathol. 1998;29:1097-1104.
34. Lefkowitz M, Lefkowitz W, Wargotz ES. Intraductal (intracystic) papillary carcinoma of the breast and its variants: a clinicopathological study of 77 cases. Hum Pathol. 1994;25:802-809.
35. Solorzano CC, Middleton LP, Hunt KK, et al. Treatment and outcome of patients with intracystic papillary carcinoma of the breast. Am J Surg. 2002;184:364-368.
36. Chuba PJ, Hamre MR, Yap J, et al. Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data. J Clin Oncol. 2005;23:5534-5541.
37. Crisi GM, Mandavilli S, Cronin E, et al. Invasive mammary carcinoma after immediate and short-term follow-up for lobular neoplasia on core biopsy. Am J Surg Pathol. 2003;27:325-333.
38. Elsheikh TM, Silverman JF. Follow-up surgical excision is indicated when breast core needle biopsies show atypical lobular hyperplasia or lobular carcinoma in situ: a correlative study of 33 patients with review of the literature. Am J Surg Pathol. 2005;29:534-543.
39. Fisher ER, Costantino J, Fisher B, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Five-year observations concerning lobular carcinoma in situ. Cancer. 1996;78:1403-1416.
40. Fisher ER, Land SR, Fisher B, et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: twelve-year observations concerning lobular carcinoma in situ. Cancer. 2004;100:238-244.
41. Leonard GD, Swain SM. Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst. 2004;96:906-920.
42. Li CI, Malone KE, Saltzman BS, et al. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001. Cancer. 2006;106:2104-2112.
43. Maluf H, Koerner F. Lobular carcinoma in situ and infiltrating ductal carcinoma: frequent presence of DCIS as a precursor lesion. Int J Surg Pathol. 2001;9:127-131.
44. Winchester DP, Jeske JM, Goldschmidt RA. The diagnosis and management of ductal carcinoma in-situ of the breast. CA Cancer J Clin. 2000;50:184-200.
45. Bedrosian I, Mick R, Orel SG, et al. Changes in the surgical management of patients with breast carcinoma based on preoperative magnetic resonance imaging. Cancer. 2003;98:468-473.
46. Molland JG, Donnellan M, Janu NC, et al. Infiltrating lobular carcinoma - a comparison of diagnosis, management and outcome with infiltrating duct carcinoma. Breast. 2004;13:389-396.
47. Munot K, Dall B, Achuthan R, et al. Role of magnetic resonance imaging in the diagnosis and single-stage surgical resection of invasive lobular carcinoma of the breast. Br J Surg. 2002;89:1296-1301.
48. Borst MJ, Ingold JA. Metastatic patterns of invasive lobular versus invasive ductal carcinoma of the breast. Surgery. 1993;114:637-641; discussion 641-642.
49. Harris M, Howell A, Chrissohou M, et al. A comparison of the metastatic pattern of infiltrating lobular carcinoma and infiltrating duct carcinoma of the breast. Br J Cancer. 1984;50:23-30.
50. Jain S, Fisher C, Smith P, et al. Patterns of metastatic breast cancer in relation to histological type. Eur J Cancer. 1993;29A:2155-2157.
51. Tham YL, Sexton K, Kramer R, et al. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer. 2006;107:696-704.
52. Arpino G, Bardou VJ, Clark GM, et al. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res. 2004;6:R149-R156.
53. Mersin H, Yildirim E, Gulben K, et al. Is invasive lobular carcinoma different from invasive ductal carcinoma? Eur J Surg Oncol. 2003;29:390-395.
54. Kneeshaw PJ, Turnbull LW, Smith A, et al. Dynamic contrast enhanced magnetic resonance imaging aids the surgical management of invasive lobular breast cancer. Eur J Surg Oncol. 2003;29:32-37.
55. Schelfout K, Van Goethem M, Kersschot E, et al. Preoperative breast MRI in patients with invasive lobular breast cancer. Eur Radiol. 2004;14:1209-1216.
56. Cocquyt VF, Blondeel PN, Depypere HT, et al. Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma. Eur J Surg Oncol. 2003;29:361-367.
57. Cristofanilli M, Gonzalez-Angulo A, Sneige N, et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol. 2005;23:41-48.
58. Mathieu MC, Rouzier R, Llombart-Cussac A, et al. The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. Eur J Cancer. 2004;40:342-351.
59. Tubiana-Hulin M, Stevens D, Lasry S, et al. Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution. Ann Oncol. 2006;17:1228-1233.
60. Acs G, Lawton TJ, Rebbeck TR, et al. Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. Am J Clin Pathol. 2001;115:85-98.
61. Gamallo C, Palacios J, Suarez A, et al. Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma. Am J Pathol. 1993;142:987-993.
62. Moll R, Mitze M, Frixen UH, et al. Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. Am J Pathol. 1993;143:1731-1742.
63. Berx G, Cleton-Jansen AM, Nollet F, et al. E-cadherin is a tumour/ invasion suppressor gene mutated in human lobular breast cancers. Embo J. 1995;14:6107-6115.
64. Berx G, Cleton-Jansen AM, Strumane K, et al. E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene. 1996;13:1919-1925.
65. Vos CB, Cleton-Jansen AM, Berx G, et al. E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. Br J Cancer. 1997;76:1131-1133.
66. Handschuh G, Candidus S, Luber B, et al. Tumour-associated E-cadherin mutations alter cellular morphology, decrease cellular adhesion and increase cellular motility. Oncogene. 1999;18:4301-4312.
67. Aberle H, Schwartz H, Kemler R. Cadherin-catenin complex: protein interactions and their implications for cadherin function. J Cell Biochem. 1996;61:514-523.
68. Aghib DF, McCrea PD. The E-cadherin complex contains the src substrate p120. Exp Cell Res. 1995;218:359-369.
69. Gooding JM, Yap KL, Ikura M. The cadherin-catenin complex as a focal point of cell adhesion and signalling: new insights from three-dimensional structures. Bioessays. 2004;26:497-511.
70. Piepenhagen PA, Nelson WJ. Defining E-cadherin-associated protein complexes in epithelial cells: plakoglobin, beta- and gamma-catenin are distinct components. J Cell Sci. 1993;104(Pt 3):751-762.
71. Reynolds AB, Daniel J, McCrea PD, et al. Identification of a new catenin: the tyrosine kinase substrate p120cas associates with E-cadherin complexes. Mol Cell Biol. 1994;14:8333-8342.
72. Yap AS, Niessen CM, Gumbiner BM. The juxtamembrane region of the cadherin cytoplasmic tail supports lateral clustering, adhesive strengthening, and interaction with p120ctn. J Cell Biol. 1998;141:779-789.
73. Shibamoto S, Hayakawa M, Takeuchi K, et al. Association of p120, a tyrosine kinase substrate, with E-cadherin/catenin complexes. J Cell Biol. 1995;128:949-957.
74. Davis MA, Ireton RC, Reynolds AB. A core function for p120-catenin in cadherin turnover. J Cell Biol. 2003;163:525-534.
75. Noren NK, Liu BP, Burridge K, et al. p120 catenin regulates the actin cytoskeleton via Rho family GTPases. J Cell Biol. 2000;150:567-580.
76. Dabbs D, Kapali M, Chivukula M, et al. The spectrum of morphomolecular abnormalities of the e-cadherin/catenin complex in pleomorphic lobular carcinoma of the breast. Appl Immunohistochem Mol Morphol. In press.
77. Berx G, Van Roy F. The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res. 2001;3:289-293.
78. Berx G, Nollet F, van Roy F. Dysregulation of the E-cadherin/catenin complex by irreversible mutations in human carcinomas. Cell Adhes Commun. 1998;6:171-184.
79. Karabakhtsian R, Johnson R, Sumkin J, et al. The clinical significance of lobular neoplasia on breast core biopsy. Am J Surg Pathol. In press.
80. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869-10874.
81. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006;19:264-271.
82. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367-5374.
83. Bryan BB, Schnitt SJ, Collins LC. Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod Pathol. 2006;19:617-621.
84. Dabbs DJ, Chivukula M, Carter G, et al. Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile. Mod Pathol. 2006;19:1506-1511.
85. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492-2502.
86. van de Rijn M, Perou CM, Tibshirani R, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol. 2002;161:1991-1996.
87. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100:8418-8423.
88. Luna-More S, Gonzalez B, Acedo C, et al. Invasive micropapillary carcinoma of the breast. A new special type of invasive mammary carcinoma. Pathol Res Pract. 1994;190:668-674.
89. Siriaunkgul S, Tavassoli FA. Invasive micropapillary carcinoma of the breast. Mod Pathol. 1993;6:660-662.
90. Li YS, Kaneko M, Sakamoto DG, et al. The reversed apical pattern of MUC1 expression is characteristics of invasive micropapillary carcinoma of the breast. Breast Cancer. 2006;13:58-63.
91. Nassar H, Pansare V, Zhang H, et al. Pathogenesis of invasive micropapillary carcinoma: role of MUC1 glycoprotein. Mod Pathol. 2004;17:1045-1050.
92. Guo X, Chen L, Lang R, et al. Invasive micropapillary carcinoma of the breast: association of pathologic features with lymph node metastasis. Am J Clin Pathol. 2006;126:740-746.
93. Nassar H. Carcinomas with micropapillary morphology: clinical significance and current concepts. Adv Anat Pathol. 2004;11:297-303.
94. Nassar H, Wallis T, Andea A, et al. Clinicopathologic analysis of invasive micropapillary differentiation in breast carcinoma. Mod Pathol. 2001;14:836-841.
95. Pettinato G, Manivel CJ, Panico L, et al. Invasive micropapillary carcinoma of the breast: clinicopathologic study of 62 cases of a poorly recognized variant with highly aggressive behavior. Am J Clin Pathol. 2004;121:857-866.
96. Walsh MM, Bleiweiss IJ. Invasive micropapillary carcinoma of the breast: eighty cases of an underrecognized entity. Hum Pathol. 2001;32:583-589.
97. Paterakos M, Watkin WG, Edgerton SM, et al. Invasive micropapillary carcinoma of the breast: a prognostic study. Hum Pathol. 1999;30:1459-1463.
98. Hartmann LC, Sellers TA, Frost MH, et al. Benign breast disease and the risk of breast cancer. N Engl J Med. 2005;353:229-237.
99. London SJ, Connolly JL, Schnitt SJ et al. A prospective study of benign breast disease and the risk of breast cancer. JAMA. 1992;267:941-944.
100. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985;312:146-151.
101. Page DL, Vander Zwaag R, Rogers LW, et al. Relation between component parts of fibrocystic disease complex and breast cancer. J Natl Cancer Inst. 1978;61:1055-1063.
102. Lacroix-Triki M, Mery E, Voigt JJ, et al. Value of cytokeratin 5/6 immunostaining using D5/16 B4 antibody in the spectrum of proliferative intraepithelial lesions of the breast. A comparative study with 34betaE12 antibody. Virchows Arch. 2003;442:548-554.
103. Moinfar F, Man YG, Lininger RA, et al. Use of keratin 35betaE12 as an adjunct in the diagnosis of mammary intraepithelial neoplasia-ductal type - benign and malignant intraductal proliferations. Am J Surg Pathol. 1999;23:1048-1058.
104. Otterbach F, Bankfalvi A, Bergner S et al. Cytokeratin 5/6 immunohistochemistry assists the differential diagnosis of atypical proliferations of the breast. Histopathology. 2000;37:232-240.
105. Rabban JT, Koerner FC, Lerwill MF. Solid papillary ductal carcinoma in situ versus usual ductal hyperplasia in the breast: a potentially difficult distinction resolved by cytokeratin 5/6. Hum Pathol. 2006;37:787-793.
106. Bader AA, Tio J, Petru E, et al. T1 breast cancer: identification of patients at low risk of axillary lymph node metastases. Breast Cancer Res Treat. 2002;76:11-17.
107. Barth A, Craig PH, Silverstein MJ. Predictors of axillary lymph node metastases in patients with T1 breast carcinoma. Cancer. 1997;79:1918-1922.
108. Chadha M, Chabon AB, Friedmann P, et al. Predictors of axillary lymph node metastases in patients with T1 breast cancer. A multivariate analysis. Cancer. 1994;73:350-353.
109. Gajdos C, Tartter PI, Bleiweiss IJ. Lymphatic invasion, tumor size, and age are independent predictors of axillary lymph node metastases in women with T1 breast cancers. Ann Surg. 1999;230:692-696.
110. Van den Eynden GG, Van der Auwera I, Van Laere SJ, et al. Distinguishing blood and lymph vessel invasion in breast cancer: a prospective immunohistochemical study. Br J Cancer. 2006;94:1643-1649.
111. Amparo RS, Angel CD, Ana LH, et al. Inflammatory breast carcinoma: pathological or clinical entity? Breast Cancer Res Treat. 2000;64:269-273.
112. Bonnier P, Charpin C, Lejeune C, et al. Inflammatory carcinomas of the breast: a clinical, pathological, or a clinical and pathological definition? Int J Cancer. 1995;62:382-385.
113. Le MG, Arriagada R, Contesso G, et al. Dermal lymphatic emboli in inflammatory and noninflammatory breast cancer: a French-Tunisian joint study in 337 patients. Clin Breast Cancer. 2005;6:439-445.
114. Kahn HJ, Bailey D, Marks A. Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and a subset of angiosarcomas. Mod Pathol. 2002;15:434-440.
115. Kahn HJ, Marks A. A new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors. Lab Invest. 2002;82:1255-1257.
116. Carter MR, Hornick JL, Lester S, et al. Spindle cell (sarcomatoid) carcinoma of the breast: a clinicopathologic and immunohistochemical analysis of 29 cases. Am J Surg Pathol. 2006;30:300-309.
117. Davis WG, Hennessy B, Babiera G, et al. Metaplastic sarcomatoid carcinoma of the breast with absent or minimal overt invasive carcinomatous component: a misnomer. Am J Surg Pathol. 2005;29:1456-1463.
118. Adem C, Reynolds C, Adlakha H, et al. Wide spectrum screening keratin as a marker of metaplastic spindle cell carcinoma of the breast: an immunohistochemical study of 24 patients. Histopathology. 2002;40:556-562.
119. Tse GM, Tan PH, Chaiwun B, et al. p63 is useful in the diagnosis of mammary metaplastic carcinomas. Pathology. 2006;38:16-20.
120. Ellis IO, Bell J, Ronan JE, et al. Immunocytochemical investigation of intermediate filament proteins and epithelial membrane antigen in spindle cell tumours of the breast. J Pathol. 1988;154:157-165.
121. Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. III. Carcinosarcoma. Cancer. 1989;64:1490-1499.
122. Sommers CL, Walker-Jones D, Heckford SE, et al. Vimentin rather than keratin expression in some hormone-independent breast cancer cell lines and in oncogene-transformed mammary epithelial cells. Cancer Res. 1989;49:4258-4263.
123. Dunne B, Lee AH, Pinder SE, et al. An immunohistochemical study of metaplastic spindle cell carcinoma, phyllodes tumor and fibromatosis of the breast. Hum Pathol. 2003;34:1009-1015.
124. Leibl S, Gogg-Kammerer M, Sommersacher A, et al. Metaplastic breast carcinomas: are they of myoepithelial differentiation?: immunohistochemical profile of the sarcomatoid subtype using novel myoepithelial markers. Am J Surg Pathol. 2005;29:347-353.
125. Miettinen M, Franssila K. Immunohistochemical spectrum of malignant melanoma. The common presence of keratins. Lab Invest. 1989;61:623-628.
126. Zarbo RJ, Gown AM, Nagle RB, et al. Anomalous cytokeratin expression in malignant melanoma: one- and two-dimensional western blot analysis and immunohistochemical survey of 100 melanomas. Mod Pathol. 1990;3:494-501.
127. Pusztaszeri MP, Seelentag W, Bosman FT. Immunohistochemical expression of endothelial markers CD31, CD34, von Willebrand factor, and Fli-1 in normal human tissues. J Histochem Cytochem. 2006;54:385-395.
128. Miettinen M, Lindenmayer AE, Chaubal A. Endothelial cell markers CD31, CD34, and BNH9 antibody to H- and Y-antigens - evaluation of their specificity and sensitivity in the diagnosis of vascular tumors and comparison with von Willebrand factor. Mod Pathol. 1994;7:82-90.
129. Mai KT, Yazdi HM, Perkins DG. Mammary Paget's disease: evidence of diverse origin of the disease with a subgroup of Paget's disease developing from the superficial portion of lactiferous duct and a discontinuous pattern of tumor spread. Pathol Int. 1999;49:956-961.
130. Ordonez NG, Awalt H, Mackay B. Mammary and extramammary Paget's disease. An immunocytochemical and ultrastructural study. Cancer. 1987;59:1173-1183.
131. Wood WS, Hegedus C. Mammary Paget's disease and intraductal carcinoma. Histologic, histochemical, and immunocytochemical comparison. Am J Dermatopathol. 1988;10:183-188.
132. Kollmorgen DR, Varanasi JS, Edge SB, et al. Paget's disease of the breast: a 33-year experience. J Am Coll Surg. 1998;187:171-177.
133. Yim JH, Wick MR, Philpott GW, et al. Underlying pathology in mammary Paget's disease. Ann Surg Oncol. 1997;4:287-292.
134. Requena L, Sanchez Yus E, Nunez C, et al. Epidermotropically metastatic breast carcinomas. Rare histopathologic variants mimicking melanoma and Paget's disease. Am J Dermatopathol. 1996;18:385-395.
135. Chaudary MA, Millis RR, Lane EB, et al. Paget's disease of the nipple: a ten year review including clinical, pathological, and immunohistochemical findings. Breast Cancer Res Treat. 1986;8:139-146.
136. Anderson JM, Ariga R, Govil H, et al. Assessment of Her-2/Neu status by immunohistochemistry and fluorescence in situ hybridization in mammary Paget disease and underlying carcinoma. Appl Immunohistochem Mol Morphol. 2003;11:120-124.
137. Haerslev T, Krag Jacobsen G. Expression of cytokeratin and erbB-2 oncoprotein in Paget's disease of the nipple. An immunohistochemical study. Apmis. 1992;100:1041-1047.
138. Lammie GA, Barnes DM, Millis RR et al. An immunohistochemical study of the presence of c-erbB-2 protein in Paget's disease of the nipple. Histopathology. 1989;15:505-514.
139. Wolber RA, Dupuis BA, Wick MR. Expression of c-erbB-2 oncoprotein in mammary and extramammary Paget's disease. Am J Clin Pathol. 1991;96:243-247.
140. Meissner K, Riviere A, Haupt G, et al. Study of neu-protein expression in mammary Paget's disease with and without underlying breast carcinoma and in extramammary Paget's disease. Am J Pathol. 1990;137:1305-1309.
141. Gillett CE, Bobrow LG, Millis RR. S100 protein in human mammary tissue - immunoreactivity in breast carcinoma, including Paget's disease of the nipple, and value as a marker of myoepithelial cells. J Pathol. 1990;160:19-24.
142. Lundquist K, Kohler S, Rouse RV. Intraepidermal cytokeratin 7 expression is not restricted to Paget cells but is also seen in Toker cells and Merkel cells. Am J Surg Pathol. 1999;23:212-219.
143. Yao DX, Hoda SA, Chiu A, et al. Intraepidermal cytokeratin 7 immunoreactive cells in the non-neoplastic nipple may represent interepithelial extension of lactiferous duct cells. Histopathology. 2002;40:230-236.
144. Fu W, Lobocki CA, Silberberg BK, et al. Molecular markers in Paget disease of the breast. J Surg Oncol. 2001;77:171-178.
145. Klevesath MB, Bobrow LG, Pinder SE, et al. The value of immunohistochemistry in sentinel lymph node histopathology in breast cancer. Br J Cancer. 2005;92:2201-2205.
146. Dabbs DJ, Fung M, Landsittel D, et al. Sentinel lymph node micrometastasis as a predictor of axillary tumor burden. Breast J. 2004;10:101-105.
147. den Bakker MA, van Weeszenberg A, de Kanter AY, et al. Non-sentinel lymph node involvement in patients with breast cancer and sentinel node micrometastasis; too early to abandon axillary clearance. J Clin Pathol. 2002;55:932-935.
148. Kamath VJ, Giuliano R, Dauway EL, et al. Characteristics of the sentinel lymph node in breast cancer predict further involvement of higher-echelon nodes in the axilla: a study to evaluate the need for complete axillary lymph node dissection. Arch Surg. 2001;136:688-692.
149. Mignotte H, Treilleux I, Faure C, et al. Axillary lymph-node dissection for positive sentinel nodes in breast cancer patients. Eur J Surg Oncol. 2002;28:623-626.
150. Cserni G, Bianchi S, Vezzosi V, et al. The value of cytokeratin immunohistochemistry in the evaluation of axillary sentinel lymph nodes in patients with lobular breast carcinoma. J Clin Pathol. 2006;59:518-522.
151. DeYoung BR, Wick MR. Immunohistologic evaluation of metastatic carcinomas of unknown origin: an algorithmic approach. Semin Diagn Pathol. 2000;17:184-193.
152. Rubin BP, Skarin AT, Pisick E, et al. Use of cytokeratins 7 and 20 in determining the origin of metastatic carcinoma of unknown primary, with special emphasis on lung cancer. Eur J Cancer Prev. 2001;10:77-82.
153. Tot T. Adenocarcinomas metastatic to the liver: the value of cytokeratins 20 and 7 in the search for unknown primary tumors. Cancer. 1999;85:171-177.
154. Perry A, Parisi JE, Kurtin PJ. Metastatic adenocarcinoma to the brain: an immunohistochemical approach. Hum Pathol. 1997;28:938-943.
155. Wick MR, Lillemoe TJ, Copland GT, et al. Gross cystic disease fluid protein-15 as a marker for breast cancer: immunohistochemical analysis of 690 human neoplasms and comparison with alpha-lactalbumin. Hum Pathol. 1989;20:281-287.
156. Dabbs DJ, Landreneau RJ, Liu Y, et al. Detection of estrogen receptor by immunohistochemistry in pulmonary adenocarcinoma. Ann Thorac Surg. 2002;73:403-405; discussion 406.
157. Nash JW, Morrison C, Frankel WL. The utility of estrogen receptor and progesterone receptor immunohistochemistry in the distinction of metastatic breast carcinoma from other tumors in the liver. Arch Pathol Lab Med. 2003;127:1591-1595.
158. Wallace ML, Longacre TA, Smoller BR. Estrogen and progesterone receptors and anti-gross cystic disease fluid protein 15 (BRST-2) fail to distinguish metastatic breast carcinoma from eccrine neoplasms. Mod Pathol. 1995;8:897-901.
159. Ciampa A, Fanger G, Khan A, et al. Mammaglobin and CRxA-01 in pleural effusion cytology: potential utility of distinguishing metastatic breast carcinomas from other cytokeratin 7-positive/cytokeratin 20-negative carcinomas. Cancer. 2004;102:368-372.
160. Han JH, Kang Y, Shin HC, et al. Mammaglobin expression in lymph nodes is an important marker of metastatic breast carcinoma. Arch Pathol Lab Med. 2003;127:1330-1334.
161. Bhargava R, Beriwal S, Dabbs DJ. Mammaglobin versus GCDFP-15: an immunohistologic validation survey of sensitivity and specificity. Am J Clin Pathol. 2007;127:103-113.
162. Wick MR, Ockner DM, Mills SE, et al. Homologous carcinomas of the breasts, skin, and salivary glands. A histologic and immunohistochemical comparison of ductal mammary carcinoma, ductal sweat gland carcinoma, and salivary duct carcinoma. Am J Clin Pathol. 1998;109:75-84.